INSULIN

Biocon, Mylan's diabetic drug receives positive opinion from European Medicines Agency

Biocon said the CHMP positive opinion will be considered by the European Commission. The European Commission decision on the approval is ex...

View: A quickfire vaccine might not be as beneficial for the world as it is for big pharma

Meanwhile, big pharma has convinced regulators that its vaccines are good enough for nationwide immunisation. Concocting this vaccine only ...

COVID pandemic underlined importance of integrated healthcare system: Jitendra Singh

Jitendra Singh, a renowned diabetologist, said that even during the pre-COVID era, it was proven with evidence that in the treatment of non...

Amazon launches online pharmacy to sell prescription drugs, shaking up pharma industry

Now at Amazon.com: insulin and inhalers. The online colossus opened an online pharmacy Tuesday that allows customers to order medication or...

World Diabetes Day: Manage stress; it is affecting your response to insulin

Stress is associated with unhealthy lifestyle like poor sleep pattern, bad eating habits, etc.

Biocon Biologics to expand to Latin America, Africa and Asia

“We are investing thoughtfully to expand the global footprint step by step across the world. We have opened regional offices across Latin A...

Biocon Q2 results: Net profit drops 22% on higher R&D cost; revenue jumps 10%

Biocon reported a 10% rise in total revenue to Rs 1,760 crore driven by overall growth in generics, biosimilar and research services busine...

View: India’s pharma industry needs innovation-promoting and smart regulation to up its game

The Indian pharmaceutical industry is a fine example of how such investment in R&D, combined with supportive public policy, has created glo...

In insulin bio-similars, our only competitors are original manufacturers: Kiran Mazumdar Shaw, Biocon

Kiran Majumdar Shaw, chairperson & MD, Biocon, talks on strengthening market share in bio-similars and how big a role it will play in the c...

Glargine launch in US opens up a huge opportunity for Biocon: Kiran Mazumdar Shaw

Even as a biosimilar, it is estimated to be a $2.2-billion opportunity for Biocon and Mylan.

Biocon Biologics, Voluntis tie up on digital therapeutics for people with diabetes

Insulia provides automated insulin dose recommendations and coaching messages for people with diabetes, while enabling the healthcare team ...

Biocon partners with Voluntis to develop digital therapeutics for diabetes patients

The licensing agreement, signed between Biocon Biologics’ subsidiary Biocon Sdn. Bhd., Malaysia and Voluntis, would make Biocon Biologics o...

Biocon gets US FDA nod to launch insulin glargine

The product branded as Semglee has an identical amino acid sequence to Sanofi’s Lantus® and is approved for the same indications. This is t...

Biocon, Mylan win US court ruling in favour of insulin Glargine

US District Court of New Jersey found the device patent claims (US Patent No. 9526844) asserted by Sanofi against Biocon and Mylan’s insuli...

Biocon sees a sweet spot with its affordable insulin in US

The biotech firm is also planning to provide its rh-insulin to middle- and low-income countries at less than 10 cents a day. Biocon Biologi...

Volume with low cost is Biocon Biologics’ big plan

The Biocon subsidiary will chart a path that ensures high volumes and low costs, unlike competitors. The company plans to create an ecosyst...

Biocon to reduce insulin prices to 10 cents per day

Kiran Mazumdar Shaw, chairperson and managing director, Biocon said accessibility of insulin has been a major concern over the years due to...